A376930 Stock Overview
Noul Co., Ltd. engages in the in vitro diagnosis and remote diagnosis business worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Noul Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,390.00 |
| 52 Week High | ₩8,520.00 |
| 52 Week Low | ₩1,987.50 |
| Beta | -0.29 |
| 1 Month Change | -9.47% |
| 3 Month Change | -24.96% |
| 1 Year Change | -37.02% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -48.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| A376930 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | 14.9% | -0.2% | 2.1% |
| 1Y | -37.0% | 27.6% | 6.6% |
Return vs Industry: A376930 underperformed the KR Medical Equipment industry which returned 27.6% over the past year.
Return vs Market: A376930 underperformed the KR Market which returned 6.6% over the past year.
Price Volatility
| A376930 volatility | |
|---|---|
| A376930 Average Weekly Movement | 7.3% |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A376930's share price has been volatile over the past 3 months.
Volatility Over Time: A376930's weekly volatility has decreased from 15% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 117 | David Lim | www.noul.kr |
Noul Co., Ltd. engages in the in vitro diagnosis and remote diagnosis business worldwide. It offers miLab, an AI-based blood diagnostic medical device that automates sample preparation, imaging, and analysis. The company also provides malaria diagnostics, blood cell morphology analysis, cancer morphology, and immunohistochemistry services.
Noul Co.,Ltd. Fundamentals Summary
| A376930 fundamental statistics | |
|---|---|
| Market cap | ₩88.30b |
| Earnings (TTM) | -₩16.32b |
| Revenue (TTM) | ₩2.73b |
32.3x
P/S Ratio-5.4x
P/E RatioIs A376930 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A376930 income statement (TTM) | |
|---|---|
| Revenue | ₩2.73b |
| Cost of Revenue | ₩2.65b |
| Gross Profit | ₩85.13m |
| Other Expenses | ₩16.41b |
| Earnings | -₩16.32b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -441.74 |
| Gross Margin | 3.11% |
| Net Profit Margin | -597.00% |
| Debt/Equity Ratio | 4.5% |
How did A376930 perform over the long term?
See historical performance and comparison